Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,508,328
  • Shares Outstanding, K 110,018
  • Annual Sales, $ 7,863 M
  • Annual Income, $ 2,116 M
  • 60-Month Beta 0.58
  • Price/Sales 8.78
  • Price/Cash Flow 25.90
  • Price/Book 5.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 5.59
  • Number of Estimates 1
  • High Estimate 5.59
  • Low Estimate 5.59
  • Prior Year 5.29
  • Growth Rate Est. (year over year) +5.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
575.89 +11.19%
on 06/16/20
653.53 -2.02%
on 07/07/20
+36.30 (+6.01%)
since 06/08/20
3-Month
500.87 +27.85%
on 04/09/20
653.53 -2.02%
on 07/07/20
+128.01 (+24.99%)
since 04/08/20
52-Week
271.37 +135.97%
on 09/27/19
653.53 -2.02%
on 07/07/20
+337.50 (+111.44%)
since 07/08/19

Most Recent Stories

More News
Regeneron to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2020

, /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that it will report its second quarter 2020 financial and operating results on , before the U.S. financial markets open. ...

REGN : 640.34 (-0.08%)
Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.

REGN : 640.34 (-0.08%)
GILD : 75.61 (-1.06%)
AMGN : 251.59 (-0.62%)
NVAX : 98.30 (-5.99%)
CRVS : 5.37 (+8.38%)
3 Best Performing Stocks in the S&P 500 So Far in 2020

Carrier Global (CARR), DexCom (DXCM), and Regeneron Pharmaceuticals (REGN) are the best performing stocks in the S&P 500 so far this year. This has been a particularly crazy year in the stock market. ...

CARR : 23.99 (-0.08%)
DXCM : 436.02 (+2.39%)
REGN : 640.34 (-0.08%)
Company News for Jul 8, 2020

Companies In The News Are: WMT, NVAX, DOCU, REGN.

REGN : 640.34 (-0.08%)
WMT : 125.48 (-1.16%)
NVAX : 98.30 (-5.99%)
DOCU : 206.35 (+4.35%)
Regeneron Initiates Studies on Experimental Coronavirus Drug

Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.

REGN : 640.34 (-0.08%)
SNY : 51.52 (+0.17%)
GILD : 75.61 (-1.06%)
LLY : 169.13 (+1.43%)
Novartis Gets EC Approval for Enerzair Breezhaler for Asthma

Novartis (NVS) gets EC approval for Enerzair Breezhaler as a maintenance treatment for asthma.

REGN : 640.34 (-0.08%)
RHHBY : 44.1200 (+1.17%)
NVS : 88.12 (+0.36%)
BAYRY : 18.0000 (+1.07%)
Company News for Jul 7, 2020

Companies in The News Are: BRK.B, D, UBER, REGN, SINA.

BRK.B : 181.20 (+0.03%)
REGN : 640.34 (-0.08%)
D : 75.22 (+1.35%)
SINA : 40.27 (+0.42%)
UBER : 33.93 (+3.38%)
Regeneron Utilizes Icertis Contract Management Platform for Contracting System Transformation

, /PRNewswire/ -- , the leading provider of enterprise contract management in the cloud, today announced ., has deployed the  as its contract management system. Regeneron, a leading biotechnology company...

REGN : 640.34 (-0.08%)
Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail

, /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the...

REGN : 640.34 (-0.08%)
Watch for Regeneron Pharm to Potentially Pullback After Gaining 2.39% Yesterday

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $623.56 to a high of $639.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high...

REGN : 640.34 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 659.15
1st Resistance Point 649.75
Last Price 640.34
1st Support Level 631.68
2nd Support Level 623.01

See More

52-Week High 653.53
Last Price 640.34
Fibonacci 61.8% 507.54
Fibonacci 50% 462.45
Fibonacci 38.2% 417.36
52-Week Low 271.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar